Monitoring of First-line Drug Resistance Mutations Outside the Scope of Xpert MTB/RIF Ultra is Needed for Successful Control of DR-TB in Southern Mozambique.

Mycobacterium tuberculosis Mozambique resistance conferring mutations whole-genome sequencing

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
04 Dec 2023
Historique:
received: 02 08 2023
medline: 4 12 2023
pubmed: 4 12 2023
entrez: 4 12 2023
Statut: aheadofprint

Résumé

Multidrug-resistant(MDR) tuberculosis in Southern Africa is of great concern, exacerbated by the spread of a clone harboring a mutation missed by Xpert Ultra. In Southern Mozambique, the presence of such mutation and rising cases of non-MDR isoniazid resistance highlights the need to ensure accurate detection of antimicrobial-resistance in the country.

Identifiants

pubmed: 38048599
pii: 7457396
doi: 10.1093/cid/ciad684
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
Pays : United States

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. I. C. received consultancy fees from Foundation for innovative new diagnostics for the development of the WHO mutation catalogue v1. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Auteurs

Carla Mariner-Llicer (C)

Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia (IBV), CSIC, Valencia, Spain.

Belén Saavedra Cervera (B)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Edson Mambuque (E)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Neide Gomes (N)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Shilzia Munguambe (S)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Luis Villamayor (L)

FISABIO Public Health, Valencia, Spain.

Irving Cancino-Muñoz (I)

FISABIO Public Health, Valencia, Spain.
I2SysBio, Universitat de València CSIC, Valencia, Spain.

Manuela Torres-Puente (M)

Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia (IBV), CSIC, Valencia, Spain.

Dinis Nguenha (D)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Amsterdam Institute for Global Health & Development (AIGHD), Amsterdam, The Netherlands.

Durval Respeito (D)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Gustavo Tembe (G)

Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.

Mariana G López (MG)

Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia (IBV), CSIC, Valencia, Spain.

Iñaki Comas (I)

Tuberculosis Genomics Unit, Instituto de Biomedicina de Valencia (IBV), CSIC, Valencia, Spain.
CIBER in Epidemiology and Public Health, Madrid, Spain.

Alberto L García-Basteiro (AL)

ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain.

Classifications MeSH